Cargando…
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepato...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457150/ https://www.ncbi.nlm.nih.gov/pubmed/33576035 http://dx.doi.org/10.1002/hep.31749 |
_version_ | 1784571023046213632 |
---|---|
author | Lan, Tian Yu, Yang Zhang, Jing Li, Haonan Weng, Qiqing Jiang, Shuo Tian, Song Xu, Tonghao Hu, Sha Yang, Guizhi Zhang, Yan Wang, Weixuan Wang, Lexun Zhu, Qing Rong, Xianglu Guo, Jiao |
author_facet | Lan, Tian Yu, Yang Zhang, Jing Li, Haonan Weng, Qiqing Jiang, Shuo Tian, Song Xu, Tonghao Hu, Sha Yang, Guizhi Zhang, Yan Wang, Weixuan Wang, Lexun Zhu, Qing Rong, Xianglu Guo, Jiao |
author_sort | Lan, Tian |
collection | PubMed |
description | BACKGROUND AND AIMS: Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases. APPROACH AND RESULTS: We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH. CONCLUSION: Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH. |
format | Online Article Text |
id | pubmed-8457150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84571502021-09-27 Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway Lan, Tian Yu, Yang Zhang, Jing Li, Haonan Weng, Qiqing Jiang, Shuo Tian, Song Xu, Tonghao Hu, Sha Yang, Guizhi Zhang, Yan Wang, Weixuan Wang, Lexun Zhu, Qing Rong, Xianglu Guo, Jiao Hepatology Original Articles BACKGROUND AND AIMS: Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases. APPROACH AND RESULTS: We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH. CONCLUSION: Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH. John Wiley and Sons Inc. 2021-08-26 2021-08 /pmc/articles/PMC8457150/ /pubmed/33576035 http://dx.doi.org/10.1002/hep.31749 Text en © 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Lan, Tian Yu, Yang Zhang, Jing Li, Haonan Weng, Qiqing Jiang, Shuo Tian, Song Xu, Tonghao Hu, Sha Yang, Guizhi Zhang, Yan Wang, Weixuan Wang, Lexun Zhu, Qing Rong, Xianglu Guo, Jiao Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway |
title | Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway |
title_full | Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway |
title_fullStr | Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway |
title_full_unstemmed | Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway |
title_short | Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway |
title_sort | cordycepin ameliorates nonalcoholic steatohepatitis by activation of the amp‐activated protein kinase signaling pathway |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457150/ https://www.ncbi.nlm.nih.gov/pubmed/33576035 http://dx.doi.org/10.1002/hep.31749 |
work_keys_str_mv | AT lantian cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT yuyang cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT zhangjing cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT lihaonan cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT wengqiqing cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT jiangshuo cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT tiansong cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT xutonghao cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT husha cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT yangguizhi cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT zhangyan cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT wangweixuan cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT wanglexun cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT zhuqing cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT rongxianglu cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway AT guojiao cordycepinamelioratesnonalcoholicsteatohepatitisbyactivationoftheampactivatedproteinkinasesignalingpathway |